GlassScriptPhysician profile
Amanda Comeau
NPI 1366166910
$2,519.64
in general payments reported to CMS, 2019-2025
22 companies · $916 in 2025
The $916 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $670 · 2024: $810 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,396.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $463.97 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $431.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $390.02 | 2023-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $256.98 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $111.69 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $110.92 | 2023-2025 | Capvaxive, Gardasil 9, Belsomra |
| Amgen INC. | $102.50 | 2024-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $87.04 | 2023-2025 | |
| Exact Sciences Corporation | $80.98 | 2023-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $61.59 | 2025 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.88 | 2022-2024 | Xifaxan |
| Astellas Pharma US INC | $57.98 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.35 | 2025 | Jardiance |
| Currax Pharmaceuticals LLC | $48.91 | 2022-2025 | Contrave, Onzetra Xsail |
| Idorsia Pharmaceuticals US INC | $42.43 | 2022-2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.55 | 2022-2023 | |
| Axsome Therapeutics, INC. | $26.31 | 2025 | Auvelity |
| Ars Pharmaceuticals Operations, INC. | $25.56 | 2025 | Neffy |
| Otsuka America Pharmaceutical, INC. | $23.87 | 2025 | Jynarque |
| Phathom Pharmaceuticals, INC. | $18.22 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $17.67 | 2023 | Nuzyra |
| Medtronic, INC. | $15.45 | 2024 | Closurefast |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Comeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.